Ran Nussbaum is a managing partner and co-founder of Pontifax, an investment firm focused on innovative biotech, and life science companies with approximately $1.2 billion assets under management. The fund runs more than 55 portfolio companies all around the Globe. His work revolves around constant and active involvement in companies, providing them with strategic and business development oversight. In the past, Mr. Nussbaum served on the boards of Kite pharma (sold to Gilead), cCAM Therapeutics (sold to Merck), ArQule Inc. (sold to Merck), Prevail Therapeutics (sold to Eli Lilly) and UroGen Pharma. Currently, he sits on many of Pontifax’s portfolio companies including Keros Therapeutics (NASDAQ:KROS), LB Pharma, Kamari Pharma, Lutris Therapeutics and Adcytherix Therapeutics. He also serves as Graviton Pharma’s Chairman of the board. Mr. Nussbaum co-founded Keros Therapeutics and served as its Chairman of the board from establishment until April 2023. In the past he served as CEO of Biomedix and SpearHead.